Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMOZEN6)

Drug Name
RJR-2403 Drug Info
Synonyms
Metanicotine; Rivanicline; RJR-2403; Trans-metanicotine; 15585-43-0; Rivanicline [INN]; 538-79-4; (E)-Metanicotine; UNII-6H35LF645A; NSC 66331; 3-Buten-1-amine, N-methyl-4-(3-pyridinyl)-; TC-2403; AI3-18211; CHEMBL132966; 6H35LF645A; (3E)-N-Methyl-4-(pyridin-3-yl)but-3-en-1-amine; But-3-en-1-amine, N-methyl-4-(pyridin-3-yl)-, (E)-; Pyridine, 3-(4-(methylamino)-1-butenyl)-; (E)-N-methyl-4-pyridin-3-ylbut-3-en-1-amine; (3E)-N-methyl-4-(3-pyridinyl)-3-buten-1-amine
Indication
Disease Entry ICD 11 Status REF
Cognitive impairment 6D71 Discontinued in Phase 2 [1]
Cross-matching ID
PubChem CID
5310967
CAS Number
CAS 15585-43-0
TTD Drug ID
DMOZEN6

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Nicotinic acetylcholine receptor (nAChR)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Nicotine DMWX5CO Lung cancer 2C25.0 Approved [3]
Cotinine DMCEZ1B Insecticide N.A. Approved [4]
Pancuronium DMB0VY8 Anaesthesia 9A78.6 Approved [5]
Atracurium DM42HXN Anaesthesia 9A78.6 Approved [5]
Mecamylamine DMGQFYB Essential hypertension BA00 Approved [6]
CYTISINE DMUF0BJ Tobacco dependence 6C4A.2 Phase 3 [7]
Dexefaroxan DMTY4KN Parkinson disease 8A00.0 Phase 2 [8]
BMS-954561 DM7XV4R Diabetic neuropathy 8C0Z Phase 2 [9]
ASM-024 DM35S2I Asthma CA23 Phase 2 [10]
NIC-002 DMKLJMI Nicotine dependence 6C4A.2 Phase 2 [11]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Nicotinic acetylcholine receptor (nAChR) TTJSZTB NOUNIPROTAC Agonist [2]

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 3994).
2 The therapeutic potential of nicotinic acetylcholine receptor agonists for pain control. Expert Opin Investig Drugs. 2001 Oct;10(10):1819-30.
3 Atypical antipsychotics as noncompetitive inhibitors of alpha4beta2 and alpha7 neuronal nicotinic receptors. Neuropharmacology. 2009 Aug;57(2):183-91.
4 Functional versus chemical diversity: is biodiversity important for drug discovery. Trends Pharmacol Sci. 2002 May;23(5):225-31.
5 Pharmacological characteristics of the inhibition of nondepolarizing neuromuscular blocking agents at human adult muscle nicotinic acetylcholine receptor. Anesthesiology. 2009 Jun;110(6):1244-52.
6 Mecamylamine (Inversine): an old antihypertensive with new research directions. J Hum Hypertens. 2002 Jul;16(7):453-7.
7 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
8 The pipeline and future of drug development in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):904-22.
9 EP patent application no. 2774991, Drug delivery system for use in the treatment or diagnosis of neurological disorders.
10 Effects of ASM-024, a modulator of acetylcholine receptor function, on airway responsiveness and allergen-induced responses in patients with mild asthma. Can Respir J. 2015 Jul-Aug;22(4):230-4.
11 Therapeutic advances in the treatment of nicotine addiction: present and future. Ther Adv Chronic Dis. 2010 May; 1(3): 95-106.